BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park YJ, Martin EG. Medicare Part D's Effects on Drug Utilization and Out-of-Pocket Costs: A Systematic Review. Health Serv Res 2017;52:1685-728. [PMID: 27480577 DOI: 10.1111/1475-6773.12534] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Bedard NA, Katz JN, Losina E, Opare-Addo MB, Kopp PT. Administrative Data Use in National Registry Efforts: Blessing or Curse? J Bone Joint Surg Am 2022;104:39-46. [PMID: 36260043 DOI: 10.2106/JBJS.22.00565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu J, Zhang X, Wang B, Dai H, Dou D, Fang W. Trends in anti-HER2 drugs consumption and influencing factors. Front Public Health 2022;10:944071. [DOI: 10.3389/fpubh.2022.944071] [Reference Citation Analysis]
3 Everson J, Henderson SC, Cheng A, Senft N, Whitmore C, Dusetzina SB. Demand for and Occurrence of Medication Cost Conversations: A Narrative Review. Med Care Res Rev 2022;:10775587221108042. [PMID: 35808853 DOI: 10.1177/10775587221108042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Guindon GE, Fatima T, Garasia S, Khoee K. A systematic umbrella review of the association of prescription drug insurance and cost-sharing with drug use, health services use, and health. BMC Health Serv Res 2022;22:297. [PMID: 35241088 DOI: 10.1186/s12913-022-07554-w] [Reference Citation Analysis]
5 Alnijadi AA, Yuan J, Wu J, Li M, Lu ZK. Cost-Related Medication Nonadherence (CRN) on Healthcare Utilization and Patient-Reported Outcomes: Considerations in Managing Medicare Beneficiaries on Antidepressants. Front Pharmacol 2021;12:764697. [PMID: 34950029 DOI: 10.3389/fphar.2021.764697] [Reference Citation Analysis]
6 Ng Kamstra JS, Molina T, Halliday T. Compact for care: how the Affordable Care Act marketplaces fell short for a vulnerable population in Hawaii. BMJ Glob Health 2021;6:e007701. [PMID: 34845000 DOI: 10.1136/bmjgh-2021-007701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Park J, Zhang P, Wang Y, Zhou X, Look KA, Bigman ET. High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999-2017. Diabetes Care 2021;44:1797-804. [PMID: 34183427 DOI: 10.2337/dc20-2708] [Reference Citation Analysis]
8 Park J, Look KA. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization. Health Serv Res 2021. [PMID: 33870486 DOI: 10.1111/1475-6773.13660] [Reference Citation Analysis]
9 Yeung K, Dorsey CN, Mettert K. Effect of new Medicare enrollment on health, healthcare utilization, and cost: A scoping review. J Am Geriatr Soc 2021;69:2335-43. [PMID: 33721340 DOI: 10.1111/jgs.17113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gokhale M, Dusetzina SB, Pate V, Chun DS, Buse JB, Stürmer T, Gower EW. Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. Diabetes Care 2020;43:2121-7. [PMID: 32641378 DOI: 10.2337/dc19-1880] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Erath A, Dusetzina SB. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019. JAMA Netw Open 2020;3:e203969. [PMID: 32338754 DOI: 10.1001/jamanetworkopen.2020.3969] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
12 Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB. Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. Am J Clin Dermatol 2020;21:109-17. [PMID: 31452091 DOI: 10.1007/s40257-019-00468-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Jung C, Padman R, Anwar S. The impact of Medicare part D prescription drug benefit program on generic drug prescription: A study in long-term care facilities. Medicine (Baltimore) 2019;98:e16646. [PMID: 31393363 DOI: 10.1097/MD.0000000000016646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Rai P, Zhao X, Sambamoorthi U. The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.J Pain Palliat Care Pharmacother. 2018;32:90-97. [PMID: 30676844 DOI: 10.1080/15360288.2018.1546789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lind KE, Hildreth K, Lindrooth R, Morrato E, Crane LA, Perraillon MC. Effect of Medicare Part D on Ethnoracial Disparities in Antidementia Medication Use. J Am Geriatr Soc 2018;66:1760-7. [PMID: 30095169 DOI: 10.1111/jgs.15494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]